| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -57,982 | -34,640 |
| Stock-based compensation expense | 4,859 | 3,277 |
| Depreciation expense | 184 | 134 |
| Net amortization of premiums and discounts on investments | 674 | 624 |
| Amortization of debt discount | 0 | 0 |
| Other | 242 | 289 |
| Decrease in prepaid expenses and other current assets | -337 | 2,319 |
| Decrease in other assets | 0 | 0 |
| Decrease in operating lease right-of-use assets | -776 | -509 |
| Decrease in other long-term liabilities | 0 | 0 |
| Decrease in accounts payable | -1,785 | -509 |
| Increase (decrease) in accrued expenses | 7,147 | 2,224 |
| Decrease in operating lease liabilities | -1,190 | -783 |
| Net cash used in operating activities | -48,570 | -33,020 |
| Purchases of investments | 73,069 | 55,228 |
| Proceeds from sales and maturities of investments | 128,573 | 91,094 |
| Net cash provided by (used in) investing activities | 55,504 | 35,866 |
| Proceeds from issuance of common stock, net | 2,851 | 0 |
| Repayment of notes payable | 0 | 0 |
| Repayment of long-term borrowings | 0 | 0 |
| Net cash provided by financing activities | 2,851 | 0 |
| Net increase in cash, cash equivalents, and restricted cash | 9,785 | 2,846 |
| Cash and cash equivalents at beginning of period | 17,868 | - |
| Cash and cash equivalents at end of period | 27,653 | - |
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)